[Therapy for Secondary Arthropathies: from Psoriasis and Reiter's Disease to Hemochromatosis]

Overview

Journal Internist (Berl)

Specialty General Medicine

Date 2006 Nov 15

PMID 17102998

Citations 2

Authors

A Godde

U Muller-Ladner

Affiliations

Soon will be listed here.

Abstract

Arthralgia is one of the most common complaints in Western society. The classification of joint diseases with respect to genesis is crucial for the determination of adequate treatment. For inflammatory arthropathies, treatment options have expanded significantly over the last decade. This review summarizes the current treatment of psoriatic arthritis and Reiter's disease, both belonging to the spectrum of seronegative spondyloarthropathies. Regardless of our increasing knowledge of chondrogenesis, the treatment of osteoarthritis is still more or less symptomatic. Premature age of onset and the atypical joint distribution of osteoarthritis should bring metabolic diseases, for example hemochromatosis, into consideration.

Citing Articles

A Mendelian randomization analysis of inflammatory skin disease risk due to mineral deficiencies.

Wu R, Tian H, Zhao T, Tian Y, Jin X, Zhu M Front Nutr. 2024; 11:1404117.

PMID: 39469328 PMC: 11513277. DOI: 10.3389/fnut.2024.1404117.

[Biological therapy for the treatment of rheumatic diseases].

Pierer M, Baerwald C Internist (Berl). 2008; 49(8):938-46.

PMID: 18587545 DOI: 10.1007/s00108-008-2059-2.

References

Espinoza L, Zakraoui L, Espinoza C, Gutierrez F, Jara L, Silveira L . Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol. 1992; 19(6):872-7. View

Kaltwasser J, Nash P, Gladman D, Rosen C, Behrens F, Jones P . Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004; 50(6):1939-50. DOI: 10.1002/art.20253. View

Breedveld F, Weisman M, Kavanaugh A, Cohen S, Pavelka K, van Vollenhoven R . The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had.... Arthritis Rheum. 2005; 54(1):26-37. DOI: 10.1002/art.21519. View

Leirisalo-Repo M . Reactive arthritis. Scand J Rheumatol. 2005; 34(4):251-9. DOI: 10.1080/03009740500202540. View

Bongartz T, Sutton A, Sweeting M, Buchan I, Matteson E, Montori V . Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 295(19):2275-85. DOI: 10.1001/jama.295.19.2275. View

Willkens R, Williams H, WARD J, Egger M, Reading J, Clements P . Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984; 27(4):376-81. DOI: 10.1002/art.1780270403. View

Clegg D, Reda D, Weisman M, Cush J, Vasey F, Schumacher Jr H . Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996; 39(12):2021-7. DOI: 10.1002/art.1780391211. View

Salvarani C, Macchioni P, Olivieri I, Marchesoni A, Cutolo M, Ferraccioli G . A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol. 2001; 28(10):2274-82. View

Mease P . TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis. 2004; 63(7):755-8. PMC: 1755077. DOI: 10.1136/ard.2004.020719. View

10.

Spadaro A, Riccieri V, Sensi F, Taccari E, Zoppini A . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol. 1995; 13(5):589-93. View

11.

Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I . The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol. 2001; 19(1 Suppl 22):S17-20. View

12.

Black R, OBrien W, VANSCOTT E, Auerbach R, Eisen A, Bunim J . METHOTREXATE THERAPY IN PSORIATIC ARTHRITIS; DOUBLE-BLIND STUDY ON 21 PATIENTS. JAMA. 1964; 189:743-7. View

13.

Laasila K, Laasonen L, Leirisalo-Repo M . Antibiotic treatment and long term prognosis of reactive arthritis. Ann Rheum Dis. 2003; 62(7):655-8. PMC: 1754599. DOI: 10.1136/ard.62.7.655. View

14.

Kvien T, Gaston J, Bardin T, Butrimiene I, Dijkmans B, Leirisalo-Repo M . Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis. 2004; 63(9):1113-9. PMC: 1755135. DOI: 10.1136/ard.2003.010710. View

15.

Abu-Shakra M, Gladman D, Thorne J, Long J, Gough J, Farewell V . Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol. 1995; 22(2):241-5. View

16.

Clegg D, Reda D, Mejias E, Cannon G, Weisman M, Taylor T . Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996; 39(12):2013-20. DOI: 10.1002/art.1780391210. View

17.

Rihl M, Kellner H . [Arthropathy of hereditary hemochromatosis]. Z Rheumatol. 2004; 63(1):22-9. DOI: 10.1007/s00393-004-0563-x. View

18.

Flagg S, Meador R, Hsia E, Kitumnuaypong T, Schumacher Jr H . Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum. 2005; 53(4):613-7. DOI: 10.1002/art.21323. View

19.

Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, Mottonen T, Hakola M, Korpela M . Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis. Ann Rheum Dis. 2003; 62(9):880-4. PMC: 1754652. DOI: 10.1136/ard.62.9.880. View

20.

Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, Mottonen T, Hakola M, Korpela M . Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis. 2000; 59(7):565-70. PMC: 1753182. DOI: 10.1136/ard.59.7.565. View